Tokyo Pharmaceutical announced that the key phase 3 clinical trial of urcosimod for the treatment of neurogenic corneal pain has completed the first patient enrollment.

Zhitongcaijing · 2d ago
Tokyo Pharmaceutical announced that the key phase 3 clinical trial of urcosimod for the treatment of neurogenic corneal pain has completed the first patient enrollment.